Literature DB >> 22553606

Effect of erythropoietin on the expression of HIF-1 and iNOS in retina in chronic ocular hypertension rats.

Dong-Mei Gui1, Yang Yang, Xun Li, Dian-Wen Gao.   

Abstract

AIM: To research the effect of erythropoietin (EPO) to the HIF-1\iNOS signal transduction path in retina in chronic ocular hypertension rat.
METHODS: One hundred and twenty Wistar rats were divided into 12 groups randomly. Two episcleral veins were coagulated unilaterally in rats with electric coagulator to establish the glaucoma model. PT-PCR and Western Blot analysis were used to examine the expression of Caspase-9 genes in retina. And the changes of ERG-b wave before and after were detected using EPO.
RESULTS: In EPO drug treatment group, the amplitude of ERG-b wave of retina restored remarkably. There was significant difference between two groups (P<0.05). The expressions of HIF-1\iNOS mRNA and protein in EPO drug treatment group were weakened remarkably. It was statistically different compared with the non-drug treatment group.
CONCLUSION: One of protect mechanisms of EPO to injured retina caused by chronic intraocular hypertension is through HIF-1\iNOS signal conduct path.

Entities:  

Keywords:  EPO; HIF-1; iNOS; ocular hypertension; retina

Year:  2011        PMID: 22553606      PMCID: PMC3340690          DOI: 10.3980/j.issn.2222-3959.2011.01.09

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  10 in total

1.  Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats.

Authors:  N Andrew Whitlock; Neeraj Agarwal; Jian-Xing Ma; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-03       Impact factor: 4.799

Review 2.  Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage.

Authors:  S Juul
Journal:  Acta Paediatr Suppl       Date:  2002

3.  Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage.

Authors:  Iok-Hou Pang; Elaine C Johnson; Lijun Jia; William O Cepurna; Allan R Shepard; Mark R Hellberg; Abbot F Clark; John C Morrison
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-04       Impact factor: 4.799

4.  Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats.

Authors:  Simone Böcker-Meffert; Philip Rosenstiel; Claudia Röhl; Nils Warneke; Janka Held-Feindt; Jobst Sievers; Ralph Lucius
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-06       Impact factor: 4.799

5.  Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death.

Authors:  E Morishita; S Masuda; M Nagao; Y Yasuda; R Sasaki
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

6.  Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells.

Authors:  Jochen H Weishaupt; Gundula Rohde; Esther Pölking; Anna-Leena Siren; Hannelore Ehrenreich; Mathias Bähr
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-05       Impact factor: 4.799

7.  Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury.

Authors:  Anna K Junk; Antonios Mammis; Sean I Savitz; Manjeet Singh; Steven Roth; Samit Malhotra; Pearl S Rosenbaum; Anthony Cerami; Michael Brines; Daniel M Rosenbaum
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-18       Impact factor: 11.205

8.  Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit.

Authors:  Yanlu Zhang; Ye Xiong; Asim Mahmood; Yuling Meng; Changsheng Qu; Timothy Schallert; Michael Chopp
Journal:  Brain Res       Date:  2009-07-30       Impact factor: 3.252

9.  Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head.

Authors:  Gülgün Tezel; Martin B Wax
Journal:  Arch Ophthalmol       Date:  2004-09

Review 10.  Erythropoietin and the brain: from neurodevelopment to neuroprotection.

Authors:  M Buemi; E Cavallaro; F Floccari; A Sturiale; C Aloisi; M Trimarchi; G Grasso; F Corica; N Frisina
Journal:  Clin Sci (Lond)       Date:  2002-09       Impact factor: 6.124

  10 in total
  6 in total

1.  Expression and effect of proline hydroxylase domain 2 in retina of diabetic rats.

Authors:  Zhen Li; Yi-Qiao Xing; Wei Cui; Qiang Lu
Journal:  Int J Ophthalmol       Date:  2016-03-18       Impact factor: 1.779

Review 2.  Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.

Authors:  Dapinder Kaur; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Vishnu Nayak Badavath; Syed Shams Ul Hassan; Mohammad Mehedi Hasan; Saurabh Bhatia; Ahmed Al-Harassi; Haroon Khan; Simona Bungau
Journal:  Metab Brain Dis       Date:  2021-08-26       Impact factor: 3.584

3.  Functional and Structural Effects of Erythropoietin Subconjunctival Administration in Glaucomatous Animals.

Authors:  Ana Paula Resende; Serge G Rosolen; Telmo Nunes; Berta São Braz; Esmeralda Delgado
Journal:  Biomed Hub       Date:  2018-07-13

Review 4.  Evidence That Erythropoietin Modulates Neuroinflammation through Differential Action on Neurons, Astrocytes, and Microglia.

Authors:  Wesley S Bond; Tonia S Rex
Journal:  Front Immunol       Date:  2014-10-22       Impact factor: 7.561

Review 5.  Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.

Authors:  Carolina Castillo Hernández; Carlos Felipe Burgos; Angela Hidalgo Gajardo; Tiare Silva-Grecchi; Javiera Gavilan; Jorge Roberto Toledo; Jorge Fuentealba
Journal:  Neural Regen Res       Date:  2017-09       Impact factor: 5.135

6.  Effects of chronic mild hyperoxia on retinal and choroidal blood flow and retinal function in the DBA/2J mouse model of glaucoma.

Authors:  Eric R Muir; Saurav B Chandra; Divya Narayanan; Vincent Zhang; Ike Zhang; Zhao Jiang; Jeffrey W Kiel; Timothy Q Duong
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.